Investigators to bring data on glucose management with oral orforglipron Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
Unlike injectable options, oral semaglutide is available as an easy-to-take daily tablet, making weight loss accessible without the stress of injections
Mild nausea may return for a few days after each increase
In some instances, patients administered substantially more medication than intended because of confusion over vial concentrations, syringes, or dosing instructions
It is grounded in rigorous analysis of randomised controlled trials and the EASO obesity framework